OBM_Logo_Orange_White_RGB-4

Close

  • Who We Are
    • Our Approach
    • Our People
    • Careers
  • Our Innovations
    • Pipeline
    • Therapeutic Areas
    • Virtue® SAB
    • BackBeat CNT™ (AVIM therapy)
    • FreeHold Retractors
  • Investor Relations
    • Overview
    • News & Events
    • Stock Information
    • Corporate Governance
    • Financial & Filings
    • IR Resources
  • Contact Us

We bring medical innovations to life

We are a biomedical innovation company...

accelerating high-impact technologies to patients through risk-reward sharing partnerships with leading medical device companies.

Our ApproachOur Approach

Our partnership-enabled business model focuses on forging strategic collaborations with leading medical device companies to drive successful global commercialization of products we develop.

Learn More

light bulbOur Pipeline

Our pipeline is comprised of innovative therapeutic product candidates that we believe have the potential for value creation using our partnership-enabled business model.

Learn More

our peopleOur People

We are led by a highly accomplished, multidisciplinary management team and board of directors with extensive experience in all phases of therapeutic device development.

Learn More

Our Technologies

Our two late-stage flagship technologies are designed to address large unmet needs associated with the treatment of hypertension, a significant risk factor for death worldwide and atherosclerotic artery disease, the leading cause of mortality worldwide.

BackBeat CNT

BackBeat Cardiac Neuromodulation Therapy™

BackBeat CNT™ (also known as atrioventricular interval modulation (AVIM) therapy) is an investigational patented bioelectronic treatment for hypertension that is designed to drive an immediate, substantial and persistent reduction in blood pressure while simultaneously modulating autonomic nervous system responses to maintain the reduction.

Learn more

Virtue SAB

Virtue® Sirolimus AngioInfusion™ Balloon (SAB)

Virtue SAB is an investigational patented drug/device combination product candidate for the treatment of artery disease designed to deliver a proprietary extended release formulation of sirolimus, SirolimusEFR, during balloon angioplasty without the need for balloon coating or a permanent implant.

Learn more

key facts mobile keyfacts desktop
BackBeat CNT and Virtue SAB
CNT, Sostenocel, Microporous Balloon Infusion System
Heart Failure, Opthalmic Inflammation, BPH & Urethral Strictures, Osteoarthritis, Chronic Rhinosinusitis

Virtue® SAB is investigational and not commercially approved.

BackBeat CNT™ (also known as AVIM therapy) is investigational and not commercially approved.

Orchestra BioMed logo
    •  Who We Are
      Our Approach
      Our People
      Careers
    • Our Innovations
      Pipeline
      Therapeutic Areas
      Virtue® SAB
      BackBeat CNT™
      FreeHold Retractors
    • Investor Relations
      Overview
      News & Events
      Stock Information
      Corporate Governance
      Financial & Filings
      IR Resources
    • Contact Us
      Legal

© 2025 Orchestra BioMed Inc. Virtue®, BackBeat CNT™ FreeHold Duo®, FreeHold Trio® and Orchestra BioMed™ are trademarks of Orchestra BioMed.
All other trademarks are trademarks of their respective owners.
SM-0020 Rev 01

Disclaimer